Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Menke

Showing results (71-80 of 75) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 75 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 25, 2015
Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trialG Gebhart, L E Lamberts, Z Wimana, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 16, 2017
Androgen and Estrogen Receptor Imaging in Metastatic Breast Cancer Patients as a Surrogate for Tissue BiopsiesClasina M Venema, Lemonitsa H Mammatas, Carolina P Schröder, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 10, 2019
[<sup>89</sup>Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancerE J van Helden, S G Elias, S L Gerritse, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 22, 2015
ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody-Drug Conjugate TreatmentLaetitia E Lamberts, Catharina W Menke-van der Houven van Oordt, Eva J ter Weele, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 15, 2020
Correction to: [89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancerE J van Helden, S G Elias, S L Gerritse, et al.
Pageof 8

Showing results (71-80 of 75) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 75 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 25, 2015
Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trialG Gebhart, L E Lamberts, Z Wimana, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 16, 2017
Androgen and Estrogen Receptor Imaging in Metastatic Breast Cancer Patients as a Surrogate for Tissue BiopsiesClasina M Venema, Lemonitsa H Mammatas, Carolina P Schröder, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 10, 2019
[<sup>89</sup>Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancerE J van Helden, S G Elias, S L Gerritse, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 22, 2015
ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody-Drug Conjugate TreatmentLaetitia E Lamberts, Catharina W Menke-van der Houven van Oordt, Eva J ter Weele, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 15, 2020
Correction to: [89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancerE J van Helden, S G Elias, S L Gerritse, et al.
Pageof 8